| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CSO, Head Res.& Non-clin. Dev. | Chief Scientific Officer and
1 company
William Michael Kavanaugh last filed a Form 4 in February 2020, as CSO, Head Res.& Non-clin. Dev. at CTMX.
At the last filing, the largest reported position was 19,047 shares of CTMX. The CTMX filings lean toward selling, a net 43,368 shares.
William Michael Kavanaugh has 11 Form 4 filings on record from May 2015 to February 2020, all as CSO, Head Res. & Non-clin. Dev. at CytomX Therapeutics (CTMX), 2015–2020.
The 14 reported transactions were 9 option or other derivative awards, 3 option exercises, 1 open-market sale and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $60K and 1 sale worth about $1.2M.
The only open-market purchase was 5,000 shares of CTMX at an average $12.00 on October 14, 2015, about $60K.
The only open-market sale was 48,368 shares of CTMX at an average $24.34 on October 4, 2017, about $1.2M.
Shares as reported in the last Form 4 for each company; the most recent is from February 2020. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.